LipoNMN-5 — Scientific Dossier

Ingredient Science · NAD+ Restoration

LipoNMN-5™ Scientific Dossier

Clinical evidence supporting Japanese fermented β-nicotinamide mononucleotide (β-NMN) for NAD+ restoration and healthy aging.

Prepared for LipoCentric Nutra™ Version 1.1 · Production Edition July 2026
5
Primary human clinical trials cited
250mg
Per-day dose used in the restoration & vitality trials
1,250mg
Highest daily dose evaluated for safety (4 wks)
0
Serious treatment-related adverse events reported
01 — Foundational Biology

Why NAD+ matters

A coenzyme in every living cell, feeding the reactions that keep cells energised, repaired, and resilient.

More than 500 enzymatic reactions depend directly or indirectly on NAD+ availability9 — which is why its decline is considered one of the clearest hallmarks of biological aging.

  • Cellular ATP production
  • Mitochondrial energy metabolism
  • DNA repair
  • Sirtuin activation
  • Circadian rhythm regulation
  • Oxidative stress defense
  • Cellular resilience & recovery

What drives the age-related decline

Alongside reduced NAMPT expression and general oxidative stress, four mechanisms account for most of the drop in cellular NAD+ observed with age:

Increased CD38 activity

CD38 is an enzyme that consumes NAD+. Its expression rises substantially with age, accelerating NAD+ depletion.

Mitochondrial dysfunction

Mitochondrial efficiency declines with age, simultaneously increasing NAD+ demand and reducing the efficiency of its production.

DNA damage accumulation

PARP repair enzymes consume large amounts of NAD+ every time they respond to DNA damage.

Chronic inflammation

Low-grade inflammation associated with aging further increases the rate of NAD+ turnover.

02 — The Precursor Rationale

Why NMN

A naturally occurring intermediate in the NAD+ salvage pathway, positioned one step upstream of the coenzyme itself.

After oral administration, NMN is metabolised and contributes to NAD+ biosynthesis through the body's own salvage pathway — rather than introducing a synthetic replacement for it.

  • Direct precursor to NAD+
  • Well-characterised safety profile
  • Efficient oral absorption
  • Strong biological rationale
  • Extensive preclinical evidence
  • Growing human clinical evidence
03 — Ingredient Provenance

Why Japanese fermented β-NMN

Not all NMN is manufactured the same way — sourcing and clinical validation both matter.

Mitsubishi Corporation Life Sciences

LipoNMN-5™ uses β-NMN manufactured by Mitsubishi Corporation Life Sciences Limited, using a proprietary fermentation process built on decades of Japanese microbial-fermentation know-how, with Torula yeast as the fermentation substrate. The result is a high-purity β-NMN with reduced synthetic impurities and consistent, analytically characterised manufacturing quality.

This matters because most of the human clinical evidence behind NMN as a category — including the trials summarised in this dossier — was generated using this specific fermentation-derived ingredient, not a generic or unspecified source.

≥99.0%
NMN purity (anhydrous), per manufacturer specification
5 of 5
primary trials in this dossier used NMN manufactured or supplied by Mitsubishi Corporation Life Sciences
Tokyo, JP
R&D division base for the fermentation platform
04 — Clinical Evidence

What the human trials show

Five primary human studies — four randomized, placebo-controlled trials and one open-label pilot study — covering restoration, safety, vitality, and appearance outcomes.

ANAD+ restoration

The central question for any NAD+ precursor is simple: does it actually raise NAD+ in humans? The clearest answer in this ingredient's literature comes from a 2022 trial that tracked whole-blood NAD+ over three time points.

RANDOMIZED · PLACEBO-CONTROLLED

Oral NMN safely and efficiently raises blood NAD+

Okabe K, et al. Frontiers in Nutrition. 2022;9:8686401
Dose250 mg/day
Duration4, 8 & 12 weeks
PopulationHealthy adults

Whole-blood NAD+ rose 2.5× baseline at 4 weeks, moderating to at 8 weeks and 1.7× at 12 weeks — an early peak followed by a sustained plateau. No adverse signal on liver enzymes, kidney function, blood lipids, or glucose metabolism.

BSafety profile

Across the cited trials, doses from 250 mg to 1,250 mg per day have been evaluated, with a dedicated high-dose study designed specifically to stress-test tolerability well above typical supplement dosing.

RCT · DOUBLE-BLIND · n=31

High-dose safety at 1,250 mg/day

Fukamizu Y, et al. Scientific Reports. 2022;12:14442 · Trial registry UMIN0000430842
Dose1,250 mg/day
Duration4 weeks
Population31 adults, 20–65y

No clinically meaningful change in anthropometry, hematology, biochemistry, urinalysis, or body composition, and no severe adverse events. Bacterial reverse-mutation (Ames) screening was negative — i.e., non-mutagenic.

Dose range studied Endpoints monitored Outcome
250 mg/day – 1,250 mg/day, across the cited trials Liver enzymes, renal function, hematology, lipid profile, blood glucose, uric acid, vital signs, adverse events No clinically significant abnormalities; no serious treatment-related adverse events reported

CSleep, fatigue & physical performance

The largest behavioural study in this literature followed 108 older adults for 12 weeks, and found that when NMN was taken mattered as much as whether it was taken at all.

RCT · n=108

Sleep, fatigue & lower-limb function

Kim M, et al. Nutrients. 2022;14(4):7553
Dose250 mg/day
Duration12 weeks

Afternoon dosing showed the largest gains: effect sizes of d=0.72 for sit-to-stand performance and d=0.64 for daytime drowsiness, versus morning dosing or placebo.

CHRONIC SUPPLEMENTATION

Muscle function in older men

Igarashi M, et al. npj Aging. 2022;8:55
PopulationHealthy older men
MeasureBlood NAD+ & muscle function

Chronic supplementation elevated blood NAD+ and produced measurable changes in muscle function — a complementary line of evidence to the Kim et al. findings above.

Taken together with the safety data, these chronic-use trials report favourable trends in energy, daily function, and subjective wellbeing — appropriately modest findings that build with continued use rather than appearing overnight.

DHair health & beauty science

The newest application of this evidence base moves from systemic vitality into visible, cosmetic outcomes.

OPEN-LABEL · SINGLE-ARM · n=15

Hair density and quality

Fukumoto S, et al. Cosmetics. 2025;12(5):204 · Mitsubishi Corporation Life Sciences–funded4
Dose500 mg/day
Duration12 weeks
DesignPre/post, no placebo arm

Anagen hair-elongation density rose from 55.9 to 87.7 hairs/cm², terminal hair density from 38.6 to 66.2 hairs/cm², and hair diameter from roughly 75 to 79 µm. Total hair count declined over the same window — researchers attributed this to seasonal shedding rather than treatment, but it's a fair caveat for a 15-person study (2 excluded as outliers) with no control group.

05 — Mechanisms of Action

How NAD+ restoration works at the cellular level

Mitochondria & cellular energy

Mitochondria produce roughly 90% of cellular energy, and NAD+ sits at the centre of that process.

  • Oxidative phosphorylation
  • ATP generation
  • Fatty acid oxidation
  • Glucose metabolism
  • Cellular stress resistance

Sirtuins & longevity pathways

NAD+ is the fuel that sirtuins, PARPs, and CD38 all draw from — and aging shifts that balance.

  • Sirtuins (SIRT1–7): stress resistance, DNA repair, mitochondrial biogenesis
  • PARPs: DNA repair, genomic stability
  • CD38: NAD+ turnover, immune signalling
Separately from LipoNMN-5's own formulation logic, early research has begun exploring paired NMN + apigenin regimens — apigenin is under investigation as a CD38 inhibitor, the enzyme most responsible for breaking NAD+ back down. This is an emerging research direction rather than an established one, but it does support the rationale for combining these two ingredients in the formulation below.
06 — The Formulation

The LipoNMN-5™ approach

A systems-based formulation that pairs the restoration ingredient above with four supporting compounds.

Japanese Fermented β-NMN Restoration of cellular NAD+ pools — the evidence base detailed throughout this dossier.
Trimethylglycine (TMG) Supports methylation balance during NAD+ metabolism.
Trans-Pterostilbene Supports sirtuin-related cellular pathways.
Apigenin Under investigation for its interaction with CD38-mediated NAD+ turnover.
Vitamin K2 (MK-7) Supports cardiovascular and healthy-aging physiology.
Editorial & Compliance Note

Ingredient evidence, not finished-product evidence

Every trial in this dossier was conducted on Mitsubishi's β-NMN alone — at 250 mg, 500 mg, or 1,250 mg per day — not on the finished five-ingredient LipoNMN-5 blend. The combination with TMG, pterostilbene, apigenin, and K2 is built on sound ingredient-level rationale, but it has not itself been clinically tested as a combined formula. That distinction should stay visible on the science page rather than be implied away.

Worth confirming before publishing: does a daily serving of LipoNMN-5 deliver [insert per-serving NMN dose] mg of NMN? Stating that number next to the 250 mg/500 mg benchmarks above is the single most useful credibility signal on this page — readers will do that comparison whether we make it easy or not.

07 — Scientific Conclusions

What the evidence supports — and where it stops

SUPPORTED BY CURRENT HUMAN EVIDENCE

  • Safe and well tolerated across 250 mg–1,250 mg/day
  • Significantly increases blood NAD+ levels
  • Supports healthy-aging physiology and cellular energy metabolism
  • May improve fatigue and vitality, particularly with afternoon dosing
  • May support physical performance and lower-limb function
  • Shows emerging, appearance-focused potential for hair quality

NOT YET SHOWN

  • That NMN extends human lifespan — no current evidence supports this claim
  • Direct clinical testing of the combined five-ingredient LipoNMN-5 formula
  • Long-term (multi-year) outcome data beyond the 12-week trial windows cited here

The honest version of this story is the more durable one: Japanese fermented β-NMN is among the most clinically characterised NAD+ precursor ingredients available today, and the gaps above are exactly where the next wave of research is headed.

08 — Regulatory Snapshot

Where NMN stands, market by market

A fast-moving area — accurate as of July 2026, worth reconfirming before any new market launch.

India — FSSAI

No restriction in place. NMN may be marketed as a dietary-supplement ingredient.

United States — FDA

Reversed its 2022 exclusion in September 2025; NMN is now recognised as a lawful dietary-supplement ingredient.

European Union — EFSA

Still under Novel Food review; not yet authorised for supplement sale in the EU.

This snapshot is informational, not legal advice — confirm current status with regulatory counsel for any market LipoCentric Nutra ships or advertises into.

09 — References

Select references

  1. Okabe K, Yaku K, Uchida Y, Fukamizu Y, Sato T, Sakurai T, Tobe K, Nakagawa T. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Front Nutr. 2022;9:868640.
  2. Fukamizu Y, Uchida Y, Shigekawa A, Sato T, Kosaka H, Sakurai T. Safety Evaluation of β-Nicotinamide Mononucleotide Oral Administration in Healthy Adult Men and Women. Sci Rep. 2022;12:14442.
  3. Kim M, Seol J, Sato T, Fukamizu Y, Sakurai T, Okura T. Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study. Nutrients. 2022;14(4):755.
  4. Fukumoto S, et al. Oral Supplementation of Nicotinamide Mononucleotide Improves Hair Quality and Subjective Perception of Hair Appearance in Middle-Aged Women. Cosmetics. 2025.
  5. Igarashi M, Nakagawa-Nagahama Y, Miura M, Kashiwabara K, Yaku K, Sawada M, et al. Chronic Nicotinamide Mononucleotide Supplementation Elevates Blood Nicotinamide Adenine Dinucleotide Levels and Alters Muscle Function in Healthy Older Men. npj Aging. 2022;8:5.
  6. Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Nicotinamide Mononucleotide Increases Muscle Insulin Sensitivity in Prediabetic Women. Science. 2021;372(6547):1224–1229.
  7. Chen F, Zhou D, Kong APS, Yim NT, Dai S, Chen YN, Hui LL. Efficacy of Oral Nicotinamide Mononucleotide Supplementation on Glucose and Lipid Metabolism for Adults: A Systematic Review with Meta-Analysis on Randomized Controlled Trials. Crit Rev Food Sci Nutr. 2024.
  8. Benjamin C, Crews R. Nicotinamide Mononucleotide Supplementation: Understanding Metabolic Variability and Clinical Implications. Metabolites. 2024;14(6):341.
  9. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The Hallmarks of Aging. Cell. 2013;153(6):1194–1217.